Virtual ISPOR

Under Cost Pressure, European Physicians Still Need Education on Biosimilars

May 23rd 2018

On Tuesday and Wednesday, during the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting in Baltimore, Maryland, researchers from Europe addressed the fact that, while biosimilars have a longer history in the European marketplace than they have in the United States, challenges to uptake still linger.

FDA's Mike Blum, MD, MPH, Discusses Postmarketing Surveillance of Biosimilars

May 22nd 2018

In a Monday workshop held at the International Society for Pharmacoeconomics and Outcomes Research’s 23rd Annual International Meeting, in Baltimore, Maryland, Mike Blum, MD, MPH, deputy director in the Office of Pharmacovigilance and Epidemiology at FDA, addressed the role of postmarketing surveillance in the US biosimilars market and the potential role of real-world evidence in interchangeable designations for biosimilars.

Research Highlights the Use of Anti-TNF Drugs in Treating RA

May 21st 2018

Today, at the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 23rd Annual International Meeting, held in Baltimore, Maryland, researchers addressed the complexities of using anti–tumor necrosis factor (anti-TNF) therapy in patients with rheumatoid arthritis (RA).

Study Underscores Need for Educating Community Oncologists on Biosimilars

June 2nd 2017

Research presented at the 22nd Annual International Meeting of The International Society for Pharmacoeconomics and Outcomes Research demonstrates gaps in physicians’ education on biosimilar agents.

Analysis of Physicians' Notes Shows Slow Uptake for Filgrastim-sndz

June 1st 2017

In a study presented at the 22nd Annual International Meeting of The International Society for Pharmacoeconomics and Outcomes Research, researchers sought to identify physicians’ documented granulocyte colony-stimulating factor (G-CSF) use, with a particular focus on filgrastim-sndz since its entry into the marketplace, and identified a slow US uptake for the biosimilar.

Research From Brazil Highlights the Role of Biosimilars in Reducing Private Healthcare Costs

May 31st 2017

Research Shows Patients Switching From Biosimilars to Reference Products

May 30th 2017